Product Description
Gilead Sciences is developing Filgotinib as a treatment for Rheumatoid Arthritis (RA). (Sourced from: https://www.gilead.com/news-and-press/press-room/press-releases/2020/12/gilead-and-galapagos-announce-new-commercialization-and-development-agreement-for-jyseleca-filgotinib)
Mechanisms of Action: JAK1 Inhibitor,JAK2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Gilead Sciences
Company Location: FOSTER CITY CA 94404
Company CEO: Daniel P. O’Day
Additonal Commercial Interests: Eisai
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Chile, Colombia, Croatia, Czech Republic, Estonia, France, Georgia, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Ireland, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Moldova, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Russia, Serbia, Singapore, Slovakia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Taiwan, Thailand, Ukraine, United Kingdom, United States
Active Clinical Trial Count: 21
Highest Development Phases
Phase 3: Arthritis, Rheumatoid|Colitis, Ulcerative|Crohn Disease|Spondylarthritis|Spondylitis|Spondyloarthritis
Phase 2: Arthritis, Psoriatic|Behcet Syndrome|IgG4-related Disease|Myositis|Spondylitis, Ankylosing
Phase 1: Alzheimer Disease|Arthritis, Juvenile|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-002763-34 | P3 |
Active, not recruiting |
Crohn Disease |
2030-04-01 |
|
| GLPG0634-CL-331 | P3 |
Unknown Status |
Colitis, Ulcerative |
2027-11-08 |
|
| 2022-000719-30 | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2027-06-11 |
|
| 2016-002765-58 | P3 |
Active, not recruiting |
Colitis, Ulcerative |
2026-12-23 |